From May 31st to June 4th the ASCO Annual Meeting will be held in Chicago. The theme this year is The Art and Science of Cancer Care: From Comfort to Cure. This meeting brings to McCormick Place more than 30,000 oncologists, researchers, allied science professionals and patient advocates from around the world.
I will be attending in person and posting/tweeting to X from various sessions using the #gyncsm and #ASCO24 hashtags.
The complete program may be found at https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2024-05/AM24-Program.pdf )
Below is a list of the Gynecologic Cancer sessions ( Scientific & Education).
Saturday June 1, 2024
8am Rapid Oral Abstract Session E-451
I can't wait to hear more about:
Abstract 5518: Relationship of cancer stem cell
functional assay and objective response rate of patients
with recurrent platinum-resistant ovarian cancer in a
randomized trial.
functional assay and objective response rate of patients
with recurrent platinum-resistant ovarian cancer in a
randomized trial.
Abstract 5520: Secondary cytoreduction followed by
chemotherapy versus chemotherapy alone in platinum-
sensitive relapsed ovarian cancer (SOC-1): A final overall
survival analysis of a multicenter, open-label, randomized,
phase 3 trial.
chemotherapy versus chemotherapy alone in platinum-
sensitive relapsed ovarian cancer (SOC-1): A final overall
survival analysis of a multicenter, open-label, randomized,
phase 3 trial.
1:15pm Clinical Science Symposium - Stronger Together: Novel Combinations Across the
Gynecologic Cancer Spectrum , E-451
Gynecologic Cancer Spectrum , E-451
I can't wait to hear more about:
Abstract 5509, A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patient with advanced solid tumors: Cervical cancer cohort.
Abstract 5510, Combination ATR and PARP Inhibitor(CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial
ovarian cancer (cohort A).
ovarian cancer (cohort A).
Abstract 5511, A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or
recurrent endometrial cancer.
recurrent endometrial cancer.
Sunday June 2, 2024
8:00am Oral Abstracts Hall D-2
I can't wait to hear more about:
Abstract LBA5500: Final results of BrUOG 354: A
randomized phase II trial of nivolumab alone or in
combination with ipilimumab for people with ovarian and
other extra-renal clear cell carcinomas.
randomized phase II trial of nivolumab alone or in
combination with ipilimumab for people with ovarian and
other extra-renal clear cell carcinomas.
Abstract LBA5501: Atezolizumab versus placebo in
combination with bevacizumab and non-platinum-based
chemotherapy in recurrent ovarian cancer: Final overall
and progression-free survival results from the AGO-OVAR
2.29/ENGOT-ov34 study.
combination with bevacizumab and non-platinum-based
chemotherapy in recurrent ovarian cancer: Final overall
and progression-free survival results from the AGO-OVAR
2.29/ENGOT-ov34 study.
Abstract 5502: Vibostolimab coformulated with
pembrolizumab (vibo/pembro) for previously treated
advanced mismatch repair–deficient (dMMR) endometrial
cancer: Results from cohort B1 of the phase 2
KEYVIBE-005 study.
pembrolizumab (vibo/pembro) for previously treated
advanced mismatch repair–deficient (dMMR) endometrial
cancer: Results from cohort B1 of the phase 2
KEYVIBE-005 study.
Abstract 5503: Trends in phase 3 gynecological
clinical trials of targeted therapies: Study oversight and
pharmaceutical involvement in the past 12 years.
clinical trials of targeted therapies: Study oversight and
pharmaceutical involvement in the past 12 years.
Abstract 5507: Endometrial cancer and obesity trends in
the United States in the 21st century.
First Author: Alex Andrea Francoeur, MD
the United States in the 21st century.
First Author: Alex Andrea Francoeur, MD
Case Based Panel Optimizing the Therapy Sequence in High-risk Endometrial Cancer - E451a (11:30am -12:30pm CT )
Education Session - Exploring the Uncommon: What's New in Rare Gyn Cancers
Low-Grade Serous Ovarian Cancer, Melanoma of the Gynecologic Tract, and Neuroendocrine Gynecologic Cancer will be discussed.
Monday June 3 ,2024
9am Poster Session Hall A
Posters by Topic
Biologic Correlates: Board(s) 392-396
Cervical Cancer: Board(s) 397-413, 492a-493b
Ovarian Cancer: Board(s) 414-458, 494a-500b
Uterine Cancer: Board(s) 459-488, 501a-503a
Other Gynecologic Cancer: Board(s) 489-491, 503b
Biologic Correlates: Board(s) 392-396
Cervical Cancer: Board(s) 397-413, 492a-493b
Ovarian Cancer: Board(s) 414-458, 494a-500b
Uterine Cancer: Board(s) 459-488, 501a-503a
Other Gynecologic Cancer: Board(s) 489-491, 503b
Poster sessions provide the opportunity to speak directly to researchers about their research results and to learn about early phase research. With well over 100 posters in the gyn cancer category, I will concentrate on ovarian cancer posters. Here are a few that piqued my interest.
Abstract TPS5635: A randomized, multicenter, open-
label phase III trial of hyperthermic intraperitoneal
chemotherapy in platinum-resistant recurrent ovarian
cancer (KOV-HIPEC-02). #396
label phase III trial of hyperthermic intraperitoneal
chemotherapy in platinum-resistant recurrent ovarian
cancer (KOV-HIPEC-02). #396
Abstract 5544: Tumor-informed ctDNA as an objective
marker for postoperative residual disease in epithelial
ovarian cancer. #415
marker for postoperative residual disease in epithelial
ovarian cancer. #415
Abstract 5546: Differences in physical and emotional
distress amongst patients undergoing neoadjuvant
chemotherapy versus surgery for advanced ovarian
cancer: Patient-reported outcomes at diagnosis. #417
distress amongst patients undergoing neoadjuvant
chemotherapy versus surgery for advanced ovarian
cancer: Patient-reported outcomes at diagnosis. #417
Abstract 5547: Use of cell-free DNA from ascites to
identify variants and tumour evolution in a cohort of
patients with advanced ovarian cancer #418
identify variants and tumour evolution in a cohort of
patients with advanced ovarian cancer #418
Abstract 5551: The efficacy and safety of RC88 in
patients with ovarian cancer, non-squamous-non-small-
cell lung-carcinoma and cervical cancer: Results from a
first-in-human phase 1/2 #422
patients with ovarian cancer, non-squamous-non-small-
cell lung-carcinoma and cervical cancer: Results from a
first-in-human phase 1/2 #422
Abstract 5553: Evaluation of a novel extracellular
vesicle (EV) based ovarian cancer (OC) screening test in
asymptomatic postmenopausal women #424
vesicle (EV) based ovarian cancer (OC) screening test in
asymptomatic postmenopausal women #424
Abstract 5563: The BEV1L study: Do real-world
outcomes associated with the addition of bevacizumab
to first-line chemotherapy in patients with ovarian cancer
reinforce clinical trial findings? #434
outcomes associated with the addition of bevacizumab
to first-line chemotherapy in patients with ovarian cancer
reinforce clinical trial findings? #434
Abstract 5573: Feasibility of using the handheld MasSpec
pen technology for intraoperative identification of ovarian
cancer during tumor reductive surgery. #444
pen technology for intraoperative identification of ovarian
cancer during tumor reductive surgery. #444
Abstract 5578: Artificial intelligence to predict
homologous recombination deficiency in ovarian cancer
from whole-slide histopathological images. #449
homologous recombination deficiency in ovarian cancer
from whole-slide histopathological images. #449
Abstract 5585: Germline genetic profiles of women with
ovarian malignancies: A Myriad Collaborative Research
Registry study. #456
ovarian malignancies: A Myriad Collaborative Research
Registry study. #456
Abstract TPS5625: REJOICE-Ovarian01: A phase 2/3
study of raludotatug deruxtecan (R-DXd) in patients with
platinum-resistant ovarian cancer (OVC). #494a
study of raludotatug deruxtecan (R-DXd) in patients with
platinum-resistant ovarian cancer (OVC). #494a
Abstract TPS5635: A randomized, multicenter, open-
label phase III trial of hyperthermic intraperitoneal
chemotherapy in platinum-resistant recurrent ovarian
cancer (KOV-HIPEC-02). #499a
label phase III trial of hyperthermic intraperitoneal
chemotherapy in platinum-resistant recurrent ovarian
cancer (KOV-HIPEC-02). #499a
1:15-2:30pm Education Session: State of the Art in Gyn Cancer :New Drugs and Companion Diagnostics S 100a
Immunotherapy, Anti-body drug conjugates and PARP inhibitors will be discussed
3:00-4:15 pm Educations Session: Controversies in the Surgical Management of Gyn Cancer :Balancing the Decision to Operate or Hesitate E450b
Challenges in gynecologic cancer Surgery, minimally Invasive for fertility-sparing Treatment , and the timing of debulking surgery will be discussed.
Although not specific to gyn cancers, this session on June 3rd is another one I will try to add to my schedule or watch after the meeting.
9:45 AM-11:00 AM Education Session
Solving Decades of Drug Shortages in Oncology: What, Who,
and When?
Location: S100a
Solving Decades of Drug Shortages in Oncology: What, Who,
and When?
Location: S100a
Lastly, In addition to sharing on X presenations from the meeting I will be presenting during the Harnessing the Power of Social Media: Elevating Global Oncology Practice, Research, and Education education session on June 1, 2024 (3-4pm CT) . The topic of my presentation is Social Media as an Educational Tool for Patients and Clinicians.
I am so excited that I will get to meet Drs Gil Morgan and Gilberto
Lopez, the other panelist in person . I have followed them for years on
Twitter and respect the work they have done on social media. I hope to
see you in room S402!
I look forward to taking a stroll through the Exhibit hall and spending time in the Patient Advocate Lounge meeting with other advocates. I want to give a special shout out to Jill Feldman, Lung Cancer Patient and Advocate on her Patient Advocate Award! Congratulations, Jill !
If you are attending ASCO which sessions are on your "can't miss" list?
See you in Chicago!
Dee
Every Day is a Blessing
